ClinicalTrials.gg
CompletedNCT02596126SECUREUpdated May 23, 2025Results posted

Secondary Prevention of Cardiovascular Disease in the Elderly Trial

A Phase 3 interventional study of Cardiovascular Polypill and Treatment Prevention for Secondary CV in Myocardial Infarction and Cardiovascular Disease, sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III. Completed at 113 sites in 7 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,499
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Myocardial Infarction with a site in Spain — 19 open to participants now, 27 under way, 7 of them phase 3. Myocardial Infarction · Spain.

Enrollment
26th of 98
2,499 · median 445
Started
2016
with 7 others
Phase 3
33 of 131
3 open now
Registered
68th of 131
by date
Lead sponsor
5 of 131
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Among the 131 studies in Myocardial Infarction with a site in Spain, this one is the 26th largest by enrollment of the 98 interventional ones that give a count, is one of 8 that started in 2016, is one of 33 in phase 3, and was the 68th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

19 of the 131 studies in Myocardial Infarction with a site in Spain are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Myocardial Infarction with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of a polypill strategy containing aspirin (100 mg), ramipril (2.5, 5 or 10 mgs), and atorvastatin (40 mgs) compared with the standard of care (usual care according to the local clinical practices at each participating country) in secondary prevention of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent revascularization) in elderly patients with a recent myocardial infarction.

Read the detailed description

A total number of 2499 patients have been randomized (1:1) to treatment arms. Patients will be recruited across seven countries in Europe (Spain, Italy, Germany, France, Hungary, Poland, and Czech Republic).

Patients will be ≥65 years old and diagnosed with a type 1 myocardial infarction within 6 months prior to study enrolment.

Once the inclusion and exclusion criteria are confirmed, patients will be included in the study after signing informed consent.

Randomization will take place within 6 months of the index event (AMI type I) in a 1:1 ratio to one of the two arms:

  • Cardiovascular Polypill (containing Aspirin, Ramipril, and Atorvastatin)
  • Usual care

Patients will be followed up for a minimum of 2 years and a maximum of 5 years.

There will be 3 follow up visits at month 6, 12 and 24 and telephone follow up calls at month 18, 36, 48 and 60

03

Conditions studied

  • Myocardial Infarction
  • Cardiovascular Disease

Keywords

  • Polypill
  • Prevention of Secondary Cardiovascular Disease
  • Cardiovascular Disease
  • Myocardial Infarction
  • Cardiovascular Combination Polypill AAR
  • Cardiovascular Disease in the Elderly
  • Adherence
  • SECURE
  • Elderly
  • Secondary Cardiovascular Disease
  • Secondary Cardiovascular Prevention
  • Randomized Cardiovascular Trial
  • Randomized Trial
  • Cardiovascular Polypill
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with a type 1 myocardial infarction within the previous 6 months.
  2. Subjects must be ≥65 years old, presenting with at least one of the following additional conditions:

    • Documented diabetes mellitus or previous treatment with oral hypoglycemic drugs or insulin.
    • Mild to moderate renal dysfunction: 60-30 mL/min/1.73 m2.
    • Prior myocardial infarction: defined as an AMI occurring before the index event documented in a medical report.
    • Prior coronary revascularization: coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).
    • Prior stroke: history of a documented stroke, defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue, not resulting in death.
    • Age ≥ 75 years.
  3. Signing .

Exclusion criteria

Exclusion Criteria:

  1. Unable to sign .
  2. to any of the components of the polypill.
  3. Living in a nursing home.
  4. Mental illness limiting the capacity of self-care.
  5. Participating in another clinical trial.
  6. Severe congestive heart failure ( III-IV).
  7. Severe renal disease ( (CrCl) \<30ml/min/1.73 m2).
  8. Need for oral anticoagulation at the time of randomization or planned in the future months.
  9. Any condition limiting \<2 years, including but not limited to active .
  10. Significant arrhythmias (including unresolved ventricular arrhythmias or atrial fibrillation).
  11. Scheduled coronary revascularization (patients can be randomized after final revascularization is completed within the prespecified timeframe).
  12. Do not agree to the filing, forwarding and use of his/ her pseudonymised data.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,499 participants (actual)

Study arms

  • Active comparator
    Treatment Prevention for Secondary CV

    Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating physicians..

    Drug: Treatment Prevention for Secondary CV

  • Experimental
    Cardiovascular Polypill

    Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.

    Drug: Cardiovascular Polypill

Interventions

  • DrugCardiovascular Polypill

    Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril. Participants will receive one of the following cardiovascular polypill: (A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg). or (B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).

    Also known as: Polypill

  • DrugTreatment Prevention for Secondary CV

    ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.

    Also known as: Antiplatelet agents, Lipid Lowering Agents, Renin-angiotensin-aldosterone system blockers

06

What researchers measure

Primary outcomes

  1. Major Cardiovascular Adverse Events (MACE)

    The incidence of the first occurrence of any component of the following composite endpoint, as adjudicated by the Clinical Events Committee: * Cardiovascular death. * Any nonfatal type 1 myocardial infarction. * Any nonfatal ischemic stroke. * Any urgent coronary revascularization not resulting in death.

    Time frame: Up to 5 years

Secondary outcomes

  1. Efficacy Endpoints

    Treatment adherence at 6 months measured using the Morisky-Medication Adherence Scale (8 item) Questionnaire (MMAS-8). Results: Low adherence (0-5); Medium adherence (6-7) and High adherence (8). The number and percentage of patients with low (0-5), medium (6-7) and high (8) adherence will be reported by treatment group.

    Time frame: 6 months

  2. Safety Endpoints

    All-cause mortality.

    Time frame: Up to 5 Years

  3. Efficacy Endpoints

    Treatment adherence at 24 months measured using the Morisky-Medication Adherence Scale (8 item) Questionnaire (MMAS-8). Results: Low adherence (0-5); Medium adherence (6-7) and High adherence (8). The number and percentage of patients with low (0-5), medium (6-7) and high (8) adherence will be reported by treatment group.

    Time frame: 2 years

  4. Efficacy Endpoints

    The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 1 (6 months). Mean and standard deviation will be reported by treatment group.

    Time frame: 6 months

  5. Efficacy Endpoints

    The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 2 (12 months). Mean and standard deviation will be reported by treatment group.

    Time frame: 12 months

  6. Efficacy Endpoints

    The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 3 (24 months). Mean and standard deviation will be reported by treatment group.

    Time frame: 2 years

  7. Efficacy Endpoints

    The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 1 (6 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.

    Time frame: 6 months

  8. Efficacy Endpoints

    The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 2 (12 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.

    Time frame: 12 months

  9. Efficacy Endpoints

    The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 3 (24 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.

    Time frame: 2 years

  10. Efficacy Endpoints

    Low-density lipoprotein (LDL) cholesterol levels measured in mg/dL at visit 2 (12 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.

    Time frame: 12 months

  11. Efficacy Endpoints

    Low-density lipoprotein (LDL) cholesterol levels measured in mg/dL at visit 3 (24 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.

    Time frame: 2 years

  12. Efficacy Endpoints

    The incidence of the first occurrence of any component of the following composite endpoint, as adjudicated by the Clinical Events Committee: Cardiovascular death (CV death); Acute Myocardial Infarction (MI) type 1; stroke. Measured in number of cases.

    Time frame: Up to 5 years

  13. Efficacy Endpoints

    The incidence of the first occurrence of the Cardiovascular (CV) death. Measured in number of cases.

    Time frame: Up to 5 years

  14. Efficacy Endpoints

    The incidence of the first occurrence of of the Nonfatal type 1 myocardial infarction. Measured in number of cases.

    Time frame: Up to 5 years

  15. Efficacy Endpoints

    The incidence of the first occurrence of the Nonfatal ischemic stroke. Measured in number of cases.

    Time frame: Up to 5 years

  16. Efficacy Endpoints

    The incidence of the first occurrence of the Urgent coronary revascularization. Measured in number of cases.

    Time frame: Up to 5 years

  17. Efficacy Endpoints

    Domain "effectiveness" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (effectiveness) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

    Time frame: 6 months

  18. Efficacy Endpoints

    Domain "Side effects score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain the response was on a Likert-type scale of 5 or 7 points, except for question 4 which a yes/no question about the presence of side effects is asked. If the answer to this question is no (no side effects reported by the participant), other questions will not be asked (questions 5 to 8), and the total score is automatically computed as the maximum of 100. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction.

    Time frame: 6 months

  19. Efficacy Endpoints

    Domain "Convenience score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Convenience score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

    Time frame: 6 months

  20. Efficacy Endpoints

    Domain "Global satisfaction score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Global satisfaction score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

    Time frame: 6 months

  21. Efficacy Endpoints

    Domain "effectiveness" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (effectiveness) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

    Time frame: 24 months

  22. Efficacy Endpoints

    Domain "Side effects score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Side effects score) the response was on a Likert-type scale of 5 or 7 points, except for question 4 which a yes/no question about the presence of side effects is asked. If the answer to this question is no (no side effects reported by the participant), other questions will not be asked (questions 5 to 8), and the total score is automatically computed as the maximum of 100. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction.

    Time frame: 24 months

  23. Efficacy Endpoints

    Domain "Convenience score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Convenience score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

    Time frame: 24 months

  24. Efficacy Endpoints

    Domain "Global satisfaction score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Global satisfaction score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

    Time frame: 24 months

  25. Safety Endpoints

    The incidence of the first occurrence of the Non-cardiovascular death. Measured in number of cases.

    Time frame: Up to 5 Years

07

Results

Posted May 23, 2025

Participant flow

Patients will be recruited across seven countries in Europe (Spain, Italy, Germany, France, Hungary, Poland, and Czech Republic). Patients were ≥65 years old and diagnosed with a type 1 myocardial infarction within 6 months prior to study enrolment.

Participant flow — Overall Study
MilestoneTreatment Prevention for Secondary CVCardiovascular Polypill
Started12411258
Completed12221228
Not completed1930
Withdrew: Lost to follow-up1221
Withdrew: Protocol violation79

Outcome measures

PrimaryMajor Cardiovascular Adverse Events (MACE)

The incidence of the first occurrence of any component of the following composite endpoint, as adjudicated by the Clinical Events Committee: * Cardiovascular death. * Any nonfatal type 1 myocardial infarction. * Any nonfatal ischemic stroke. * Any urgent coronary revascularization not resulting in death.

Time frame:
Up to 5 years
Reported as:
Number · number of adjudicated events
Major Cardiovascular Adverse Events (MACE)
number of adjudicated eventsTreatment Prevention for Secondary CVCardiovascular Polypill
Major Cardiovascular Adverse Events (MACE)156118
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Regression, Cox · p = < 0.025 · Hazard ratio (hr): 0.76 · 95% CI 0.6 to 0.96
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Log Rank · p = < 0.05
SecondaryEfficacy Endpoints

Treatment adherence at 6 months measured using the Morisky-Medication Adherence Scale (8 item) Questionnaire (MMAS-8). Results: Low adherence (0-5); Medium adherence (6-7) and High adherence (8). The number and percentage of patients with low (0-5), medium (6-7) and high (8) adherence will be reported by treatment group.

Time frame:
6 months
Reported as:
Number · percentage of participants
Efficacy Endpoints
percentage of participantsTreatment Prevention for Secondary CVCardiovascular Polypill
Low adherence (0-5)9.55.5
Medium adherence (6-7)27.824.0
High adherence (8)62.770.6
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Chi-squared · p = < 0.005 · Risk ratio (rr): 1.13 · 95% CI 1.06 to 1.2
SecondarySafety Endpoints

All-cause mortality.

Time frame:
Up to 5 Years
Reported as:
Number · number of events
Safety Endpoints
number of eventsTreatment Prevention for Secondary CVCardiovascular Polypill
Safety Endpoints117115
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Log Rank · p = < 0.05 · Hazard ratio (hr): 0.97 · 95% CI 0.75 to 1.25
SecondaryEfficacy Endpoints

Treatment adherence at 24 months measured using the Morisky-Medication Adherence Scale (8 item) Questionnaire (MMAS-8). Results: Low adherence (0-5); Medium adherence (6-7) and High adherence (8). The number and percentage of patients with low (0-5), medium (6-7) and high (8) adherence will be reported by treatment group.

Time frame:
2 years
Reported as:
Number · percentage of participants
Efficacy Endpoints
percentage of participantsTreatment Prevention for Secondary CVCardiovascular Polypill
Low adherence (0-5)6.94.2
Medium adherence (6-7)29.821.7
High adherence (8)63.274.1
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Chi-squared · p = < 0.005 · Hazard ratio (hr): 1.17 · 95% CI 1.1 to 1.25
SecondaryEfficacy Endpoints

The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 1 (6 months). Mean and standard deviation will be reported by treatment group.

Time frame:
6 months
Reported as:
Mean · millimeters of mercury (mmHg)
Efficacy Endpoints
millimeters of mercury (mmHg)Treatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints134.8 ± 18.1134.4 ± 17.7
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · ANCOVA · p = < 0.05 (The difference in mean change from baseline between groups will be compared using ANCOVA (adjusting for baseline levels) at 6 months, 12 months and 24 months. The difference in mean change adjusting for baseline and 95% CI will be reported.) · Mean difference (final values): -0.3 · 95% CI -1.8 to 1.2
SecondaryEfficacy Endpoints

The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 2 (12 months). Mean and standard deviation will be reported by treatment group.

Time frame:
12 months
Reported as:
Mean · millimeters of mercury (mmHg)
Efficacy Endpoints
millimeters of mercury (mmHg)Treatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints135.0 ± 18.0136.3 ± 17.5
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · ANCOVA · p = < 0.05 (The difference in mean change from baseline between groups will be compared using ANCOVA (adjusting for baseline levels) at 6 months, 12 months and 24 months. The difference in mean change adjusting for baseline and 95% CI will be reported.) · Mean difference (final values): 1.4 · 95% CI -0.1 to 3
SecondaryEfficacy Endpoints

The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 3 (24 months). Mean and standard deviation will be reported by treatment group.

Time frame:
2 years
Reported as:
Mean · millimeters of mercury (mmHg)
Efficacy Endpoints
millimeters of mercury (mmHg)Treatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints135.5 ± 17.1135.2 ± 16.9
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · ANCOVA · p = < 0.05 (The difference in mean change from baseline between groups will be compared using ANCOVA (adjusting for baseline levels) at 6 months, 12 months and 24 months. The difference in mean change adjusting for baseline and 95% CI will be reported.) · Mean difference (final values): -0.1 · 95% CI -1.7 to 1.4
SecondaryEfficacy Endpoints

The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 1 (6 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.

Time frame:
6 months
Reported as:
Mean · millimeters of mercury (mmHg)
Efficacy Endpoints
millimeters of mercury (mmHg)Treatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints74.2 ± 9.974.3 ± 10.2
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · ANCOVA · p = < 0.05 (The difference in mean change from baseline between groups will be compared using ANCOVA (adjusting for baseline levels) at 6 months, 12 months and 24 months. The difference in mean change adjusting for baseline and 95% CI will be reported.) · Mean difference (final values): 0.2 · 95% CI -0.7 to 1
SecondaryEfficacy Endpoints

The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 2 (12 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.

Time frame:
12 months
Reported as:
Mean · millimeters of mercury (mmHg)
Efficacy Endpoints
millimeters of mercury (mmHg)Treatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints74.1 ± 9.874.7 ± 9.9
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · ANCOVA · p = < 0.05 (The difference in mean change from baseline between groups will be compared using ANCOVA (adjusting for baseline levels) at 6 months, 12 months and 24 months. The difference in mean change adjusting for baseline and 95% CI will be reported.) · Mean difference (final values): 0.8 · 95% CI -0.1 to 1.6
SecondaryEfficacy Endpoints

The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 3 (24 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.

Time frame:
2 years
Reported as:
Mean · millimeters of mercury (mmHg)
Efficacy Endpoints
millimeters of mercury (mmHg)Treatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints74.9 ± 9.774.8 ± 10.1
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · ANCOVA · p = < 0.05 (The difference in mean change from baseline between groups will be compared using ANCOVA (adjusting for baseline levels) at 6 months, 12 months and 24 months. The difference in mean change adjusting for baseline and 95% CI will be reported.) · Mean difference (final values): 0.0 · 95% CI -0.9 to 1
SecondaryEfficacy Endpoints

Low-density lipoprotein (LDL) cholesterol levels measured in mg/dL at visit 2 (12 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.

Time frame:
12 months
Reported as:
Mean · mg/dL
Efficacy Endpoints
mg/dLTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints66.3 ± 25.469.2 ± 24.7
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · ANCOVA · p = < 0.05 · Mean difference (final values): 2.1 · 95% CI -0.2 to 4.4
SecondaryEfficacy Endpoints

Low-density lipoprotein (LDL) cholesterol levels measured in mg/dL at visit 3 (24 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.

Time frame:
2 years
Reported as:
Mean · mg/dL
Efficacy Endpoints
mg/dLTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints67.2 ± 25.467.7 ± 23.6
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · ANCOVA · p = < 0.05 · Mean difference (final values): -0.1 · 95% CI -2.5 to 2.4
SecondaryEfficacy Endpoints

The incidence of the first occurrence of any component of the following composite endpoint, as adjudicated by the Clinical Events Committee: Cardiovascular death (CV death); Acute Myocardial Infarction (MI) type 1; stroke. Measured in number of cases.

Time frame:
Up to 5 years
Reported as:
Number · number of events
Efficacy Endpoints
number of eventsTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints144101
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Regression, Cox · p = < 0.025 · Hazard ratio (hr): 0.70 · 95% CI 0.54 to 0.90
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Log Rank · p = < 0.05
SecondaryEfficacy Endpoints

The incidence of the first occurrence of the Cardiovascular (CV) death. Measured in number of cases.

Time frame:
Up to 5 years
Reported as:
Number · number of events
Efficacy Endpoints
number of eventsTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints7148
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Regression, Cox · p = < 0.025 · Hazard ratio (hr): 0.67 · 95% CI 0.47 to 0.97
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Log Rank · p = < 0.05
SecondaryEfficacy Endpoints

The incidence of the first occurrence of of the Nonfatal type 1 myocardial infarction. Measured in number of cases.

Time frame:
Up to 5 years
Reported as:
Number · number of events
Efficacy Endpoints
number of eventsTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints6244
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Regression, Cox · p = < 0.025 · Hazard ratio (hr): 0.71 · 95% CI 0.48 to 1.05
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Log Rank · p = < 0.05
SecondaryEfficacy Endpoints

The incidence of the first occurrence of the Nonfatal ischemic stroke. Measured in number of cases.

Time frame:
Up to 5 years
Reported as:
Number · number of events
Efficacy Endpoints
number of eventsTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints2719
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Regression, Cox · p = < 0.025 · Hazard ratio (hr): 0.70 · 95% CI 0.39 to 1.26
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Log Rank · p = < 0.05
SecondaryEfficacy Endpoints

The incidence of the first occurrence of the Urgent coronary revascularization. Measured in number of cases.

Time frame:
Up to 5 years
Reported as:
Number · number of events
Efficacy Endpoints
number of eventsTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints2827
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Regression, Cox · p = < 0.025 · Hazard ratio (hr): 0.96 · 95% CI 0.57 to 1.63
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Log Rank · p = < 0.05
SecondaryEfficacy Endpoints

Domain "effectiveness" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (effectiveness) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

Time frame:
6 months
Reported as:
Mean · score on a scale
Efficacy Endpoints
score on a scaleTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints69.17 ± 17.5772.26 ± 17.85
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · t-test, 2 sided · p = < 0.05 · Mean difference (final values): 3.09 · 95% CI 1.38 to 4.79
SecondaryEfficacy Endpoints

Domain "Side effects score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain the response was on a Likert-type scale of 5 or 7 points, except for question 4 which a yes/no question about the presence of side effects is asked. If the answer to this question is no (no side effects reported by the participant), other questions will not be asked (questions 5 to 8), and the total score is automatically computed as the maximum of 100. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction.

Time frame:
6 months
Reported as:
Mean · score on a scale
Efficacy Endpoints
score on a scaleTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints66.71 ± 23.3861.52 ± 23.18
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · t-test, 2 sided · p = < 0.05 · Mean difference (final values): -5.19 · 95% CI -12.73 to 2.35
SecondaryEfficacy Endpoints

Domain "Convenience score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Convenience score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

Time frame:
6 months
Reported as:
Mean · score on a scale
Efficacy Endpoints
score on a scaleTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints69.47 ± 16.8776.56 ± 14.78
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · t-test, 2 sided · p = < 0.05 · Mean difference (final values): 7.09 · 95% CI 5.57 to 8.62
SecondaryEfficacy Endpoints

Domain "Global satisfaction score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Global satisfaction score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

Time frame:
6 months
Reported as:
Mean · score on a scale
Efficacy Endpoints
score on a scaleTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints67.71 ± 18.5371.50 ± 18.06
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · t-test, 2 sided · p = < 0.05 · Mean difference (final values): 3.79 · 95% CI 2.04 to 5.55
SecondaryEfficacy Endpoints

Domain "effectiveness" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (effectiveness) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

Time frame:
24 months
Reported as:
Mean · score on a scale
Efficacy Endpoints
score on a scaleTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints68.79 ± 17.6574.06 ± 17.86
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · t-test, 2 sided · p = < 0.05 · Mean difference (final values): 5.26 · 95% CI 3.59 to 6.94
SecondaryEfficacy Endpoints

Domain "Side effects score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Side effects score) the response was on a Likert-type scale of 5 or 7 points, except for question 4 which a yes/no question about the presence of side effects is asked. If the answer to this question is no (no side effects reported by the participant), other questions will not be asked (questions 5 to 8), and the total score is automatically computed as the maximum of 100. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction.

Time frame:
24 months
Reported as:
Mean · score on a scale
Efficacy Endpoints
score on a scaleTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints64.20 ± 23.1468.75 ± 24.83
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · t-test, 2 sided · p = < 0.05 · Mean difference (final values): 4.55 · 95% CI -4.35 to 13.46
SecondaryEfficacy Endpoints

Domain "Convenience score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Convenience score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

Time frame:
24 months
Reported as:
Mean · score on a scale
Efficacy Endpoints
score on a scaleTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints70.19 ± 17.0677.30 ± 15.95
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · t-test, 2 sided · p = < 0.05 · Mean difference (final values): 7.11 · 95% CI 5.55 to 8.67
SecondaryEfficacy Endpoints

Domain "Global satisfaction score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Global satisfaction score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).

Time frame:
24 months
Reported as:
Mean · score on a scale
Efficacy Endpoints
score on a scaleTreatment Prevention for Secondary CVCardiovascular Polypill
Efficacy Endpoints67.76 ± 17.8774.36 ± 17.52
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · t-test, 2 sided · p = < 0.05 · Mean difference (final values): 6.60 · 95% CI 4.93 to 8.27
SecondarySafety Endpoints

The incidence of the first occurrence of the Non-cardiovascular death. Measured in number of cases.

Time frame:
Up to 5 Years
Reported as:
Number · number of events
Safety Endpoints
number of eventsTreatment Prevention for Secondary CVCardiovascular Polypill
Safety Endpoints4667
Statistical analysis
  • Treatment Prevention for Secondary CV vs Cardiovascular Polypill · Log Rank · p = < 0.05 · Hazard ratio (hr): 1.42 · 95% CI 0.97 to 2.07

Adverse events

Collected over Up to 5 Years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Prevention for Secondary CV117/1,229 (9.5%)220/1,229 (17.9%)388/1,229 (31.6%)
Cardiovascular Polypill115/1,237 (9.3%)248/1,237 (20%)404/1,237 (32.7%)
Most frequent serious events
Showing 10 of 281
Most frequent serious events
EventTreatment Prevention for Secondary CVCardiovascular Polypill
pneumoniaInfections and infestations17/122914/1237
chest painGeneral disorders15/122910/1237
covid-19 pneumoniaInfections and infestations10/122911/1237
anaemiaBlood and lymphatic system disorders9/122910/1237
acute kidney injuryRenal and urinary disorders9/12299/1237
urinary tract infectionInfections and infestations9/12296/1237
covid-19Infections and infestations5/12299/1237
cardiac failureCardiac disorders1/12298/1237
gastrointestinal haemorrhageGastrointestinal disorders4/12298/1237
haematuriaRenal and urinary disorders7/12294/1237
Most frequent other events
Showing 10 of 439
Most frequent other events
EventTreatment Prevention for Secondary CVCardiovascular Polypill
CoughRespiratory, thoracic and mediastinal disorders43/122949/1237
Chest painGeneral disorders28/122916/1237
HypotensionVascular disorders15/122926/1237
MyalgiaMusculoskeletal and connective tissue disorders25/122914/1237
HypertensionVascular disorders20/122922/1237
DyspnoeaRespiratory, thoracic and mediastinal disorders20/122917/1237
Atrial fibrillationCardiac disorders19/122916/1237
SyncopeNervous system disorders15/12298/1237
EpistaxisRespiratory, thoracic and mediastinal disorders14/122913/1237
AnaemiaBlood and lymphatic system disorders13/122912/1237

Baseline characteristics

A total of 2499 participants (Treatment Prevention for Secondary CV - 1241; Cardiovascular Polypill - 1258) were included in the study. A total of 33 (Treatment Prevention for Secondary CV - 12; Cardiovascular Polypill - 21) participants were lost to follow-up as described in the "Results Participant Flow". The results were presented for a total of 1229 participants in the "Treatment Prevention for Secondary CV" and 1237 participants in the "Cardiovascular Polypill".

Age, Categorical
Age, Categorical(Participants)Treatment Prevention for Secondary CVCardiovascular PolypillTotal
<=18 years000
Between 18 and 65 years000
>=65 years122912372466
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Prevention for Secondary CVCardiovascular PolypillTotal
Female381384765
Male8488531701
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Prevention for Secondary CVCardiovascular PolypillTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American033
White121112212432
More than one race000
Unknown or Not Reported181331
Region of Enrollment
Region of Enrollment(participants)Treatment Prevention for Secondary CVCardiovascular PolypillTotal
Hungary454590
Czechia8785172
Poland6063123
Italy365366731
France7074144
Germany184182366
Spain418422840
08

Study locations

113 sites
  • Fakultní nemocnice Královské Vinohrady
    Praha, Praha 10 10034, Czechia
  • Nemocnice Na Homolce
    Praha, Praha 5 15030, Czechia
  • Všeobecná fakultní nemocnice v Praze
    Praha 2, Praha 12808, Czechia
  • Nemocnice Rudolfa a Stefanie Benešov
    Benešov, 25601, Czechia
  • Nemocnice Jihlava
    Jihlava, 58633, Czechia
  • Krajská necmonice Liberec
    Liberec, 46030, Czechia
  • Fakultní nemocnice Olomouc
    Olomouc, 77900, Czechia
  • Nemocnice Slaný
    Slaný, 27401, Czechia
  • Nemocnice Podlesí
    Třinec, 73961, Czechia
  • Centre Hospitalier Universitaire d'Angers
    Angers, 49933, France
  • Centre Hospitalier Régional Universitaire de Besançon
    Besançon, 25030, France
  • Centre Hospitalier Universitaire de Lyon
    Bron, 69500, France
  • Centre Hospitalier Universitaire de Caen
    Caen, 14000, France
  • Centre Hospitalier Metropole Savoie
    Chambéry, 73000, France
  • Centre Hospitalier Universitaire Henri Mondor
    Créteil, 94000, France
  • Centre Hospitalier Universitaire de Dijon
    Dijon, 21000, France
  • Centre Hospitalier Universitaire de Grenoble
    Grenoble, 38000, France
  • Centre Hospitalier Régional et Universitaire de Lille
    Lille, 59037, France
  • Centre Hospitalier St Joseph St Luc
    Lyon, 69365, France
  • Centre Hospitalier Universitaire de Nice
    Nice, 06002, France
  • Hôpital Bichât
    Paris, 75010, France
  • Centre hospitalier Universitaire de Bordeaux
    Pessac, 33604, France
  • Centre Hospitalier Universitaire de Toulouse
    Toulouse, 31403, France
  • Medical Park Berlin Humboldtmühle
    Berlin - Tegel, Berlin 13507, Germany
  • Immanuel Klinikum Bernau Herzzentrum Brandenburg
    Bernau, Berlin 16321, Germany
  • Brandenburgklinik Berlin-Brandenburg GmbH, Haus Brandenburg/ Kardiologie
    Waldsiedlung, Berlin 16321, Germany
  • Klinik am See, Rehabilitationszentrum für innere Medizin
    Rüdersdorf, Brandenburg 15562, Germany
  • GLG Fachklinik Wolletzsee GmbH
    Angermünde, 16278, Germany
  • AVK Vivantes Rehabilitation GmbH
    Berlin, 12157, Germany
  • DRK- Kliniken Berlin/ Köpenick
    Berlin, 12559, Germany
  • Maria Heimsuchung Caritas-Klinik Pankow
    Berlin, 13187, Germany
  • Jüdisches Krankenhaus
    Berlin, 13347, Germany
  • Charité - Universitätsmedizin Berlin, Centrum für Schlaganfallforschung (CSB)
    Berlin, 13353, Germany
  • Vivantes Humboldt Klinikum
    Berlin, 13509, Germany
  • Vivantes Klinikum Spandu
    Berlin, 13585, Germany
  • DRK Klinik Berlin Westend
    Berlin, 14050, Germany
  • GK Havelhöhe
    Berlin, 14089, Germany
  • Gesundheitszentrum Bitterfeld /Wolfen GmbH
    Bitterfeld-Wolfen, 06749, Germany
  • Mediclin Reha-Zentrum Spreewald Fachklinik für innere Medizin
    Burg, 03096, Germany
  • MediClin Herzzentrum Coswig
    Coswig, 06869, Germany
  • Semmelweis Egyetem Városmajori Szív- és Érgyógyászati Klinika
    Budapest, 1122, Hungary
  • Fővárosi Szent János Kórház
    Budapest, 1125, Hungary
  • Szent Rókus Kórház és Intézményei
    Budapest, H-1085, Hungary
  • Békés Megyei Pándy Kálmán Kórház
    Gyula, 5700, Hungary
  • Bács- Kiskun Megyei Kórház
    Kecskemét, 6000, Hungary
  • Fejér Megyei Szent György Egyetemi Kórház
    Székesfehérvár, 8000, Hungary
  • Sydó és Tsa Kft.
    Veszprém, H-8200, Hungary
  • IRCCS Fondazione S. Maugeri Istit. di Cassano Murge
    Cassano Delle Murge, BA 70020, Italy
  • IOB-Policlinico San Marco
    Osio Sotto, BG 24040, Italy
  • Ospedale Bolognini di Seriate - ASST BERGAMO EST
    Seriate, BG 24068, Italy
  • ASST di Bergamo Ovest-Ospedale di Treviglio
    Treviglio, BG 24047, Italy
  • ASST Degli Spedali Civili di Brescia
    Brescia, BS 25123, Italy
  • Ospedale S.Lazzaro
    Alba, CN 12051, Italy
  • Ospedale Generale di Zona-Ospedale Valduce
    Como, CO 22100, Italy
  • ASL FG Ospedale "Teresa Masselli Mascia"
    San Severo, FG 71016, Italy
  • Ospedale Misericordia ASL 9 Grosseto
    Grosseto, GR 58100, Italy
  • Ospedale Sacro Cuore di Gesù
    Gallipoli, LE 73014, Italy
  • ASST Di Monza-Presidio Ospedaliero di Desio
    Desio, MB 20832, Italy
  • ASST Di Monza-Ospedale San Gerardo
    Monza, MB 20900, Italy
  • IRCCS Ospedale Policlinico di Milano
    Milano, MI 20122, Italy
  • Centro Cardiologico Monzino SpA
    Milano, MI 20138, Italy
  • ASST Santi Paolo e Carlo-Ospedale San Paolo-Polo Univ.
    Milano, MI 20142, Italy
  • IRCCS-Fondazione Don Carlo Gnocchi
    Milano, MI 20149, Italy
  • IRCCS Istituto Clinico Humanitas
    Rozzano, MI 20089, Italy
  • IRCCS Policlinico San Donato
    San Donato Milanese, MI 20097, Italy
  • Ospedale di Sassuolo S.P.A.
    Sassuolo, MO 41049, Italy
  • ASST Rhodense Ospedale di Passirana
    Passirana, Passirana-rho 20017, Italy
  • Presidio Ospedaliero San Filippo Neri-ASL Roma E
    Roma, RM 00135, Italy
  • A.O. San Camillo Forlanini
    Roma, RO 00149, Italy
  • Ospedale Ss Giovanni di Dio e Ruggi d'Aragona
    Salerno, SA 84131, Italy
  • Casa di Cura Villa Bianca
    Trento, TN 38122, Italy
  • AAS3 "Alto Friuli, Collinare, Medio Friuli" Ospedale di San Daniele del Friuli-Tolmezzo sede di S. D. del Friuli
    San Daniele Del Friuli, UD 33038, Italy
  • ASST Della Valle Olona-Ospedale di Saronno
    Saronno, VA 21047, Italy
  • Samodzielny Publiczny Szpital Kliniczny nr 7, Śląskiego Uniwersytetu Medycznego w Katowicach, Górnośląskie Centrum Medyczne im. prof. Leszka Gieca
    Katowice, Ochojec 40-635, Poland
  • Uniwersyteckie Centrum Kliniczn
    Gdańsk, 80-952, Poland
  • Szpital Wielospecjalistyczny im. Dr. Ludwika Błażka w Inowrocławiu
    Inowrocław, 88-100, Poland
  • Krakowski Szpital Specjalistyczny im. Jana Pawła II
    Kraków, 31-202, Poland
  • Zespół Opieki Zdrowotnej w Kłodzku
    Kłodzko, 57-300, Poland
  • Wojewódzki Szpital Specjalistyczny w Legnicy
    Legnica, 59-220, Poland
  • Specjalistyczny Szpital im. Dra Alfreda Sokołowskiego
    Wałbrzych, 58-309, Poland
  • Centrum Kardiologiczne "Pro Corde" Sp. z o.o.
    Wrocław, 50-315, Poland
  • Wojskowy Szpital Kliniczny z Polikliniką SP ZOZ
    Wrocław, 50-981, Poland
  • Samodzielny Publiczny Zespół Opieki Zdrowotnej w Świdnicy
    Świdnica, 58-100, Poland
  • Hospital Universitario de Cabueñes
    Gijón, Asturias 33203, Spain
  • Hospital Univeristari de Bellvitge
    L'Hospitalet De Llobregat, Barcelona 08997, Spain
  • H.C.U.de Santiago De Compostela
    Santiago De Compostela, Galicia 15706, Spain
  • Complejo Asistencial Universitario de Leon
    León, Leon 24008, Spain
  • Hospital Universitario Principe de Asturias
    Alcalá De Henares, Madrid 28805, Spain
  • Hospital General de Villalba
    Collado-Villalba, Madrid 28400, Spain
  • Hospital de Fuenlabrada
    Fuenlabrada, Madrid 28492, Spain
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitario Rey Juan Carlos
    Móstoles, Madrid 28933, Spain
  • Hospital Universitario QuironSalud Madrid
    Pozuelo De Alarcón, Madrid 28223, Spain
  • Hospital Universitario Infanta Elena
    Valdemoro, Madrid 28340, Spain
  • H.C.U. Virgen De La Arrixaca De Murcia
    El Palmar, Murcia 30120, Spain
  • Hospital Universitario A Coruña
    A Coruña, 15006, Spain
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Hospital Universitari Vall D'hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Reina Sofia de Cordoba
    Córdoba, 14004, Spain

Showing the first 100 of 113 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, Sanchez PL, Marin Ortuno F, Vazquez Rodriguez JM, Domingo-Fernandez A, Lozano I, Roncaglioni MC, Baviera M, Foresta A, Ojeda-Fernandez L, Colivicchi F, Di Fusco SA, Doehner W, Meyer A, Schiele F, Ecarnot F, Linhart A, Lubanda JC, Barczi G, Merkely B, Ponikowski P, Kasprzak M, Fernandez Alvira JM, Andres V, Bueno H, Collier T, Van de Werf F, Perel P, Rodriguez-Manero M, Alonso Garcia A, Proietti M, Schoos MM, Simon T, Fernandez Ferro J, Lopez N, Beghi E, Bejot Y, Vivas D, Cordero A, Ibanez B, Fuster V; SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022 Sep 15;387(11):967-977. doi: 10.1056/NEJMoa2208275. Epub 2022 Aug 26. PubMed 36018037 ↗
  • Buttgereit T, Palmowski A, Forsat N, Boers M, Witham MD, Rodondi N, Moutzouri E, Navidad AJQ, Van't Hof AWJ, van der Worp B, Coll-Planas L, Voshaar M, de Wit M, da Silva J, Stegemann S, Bijlsma JW, Koeller M, Mooijaart S, Kearney PM, Buttgereit F. Barriers and potential solutions in the recruitment and retention of older patients in clinical trials-lessons learned from six large multicentre randomized controlled trials. Age Ageing. 2021 Nov 10;50(6):1988-1996. doi: 10.1093/ageing/afab147. PubMed 34324628 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Oct 2021 and a completion of Mar 2022. It does not say whether these dates are actual or estimated.

Results were first posted in May 2025, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2015
First posted
Nov 4, 2015
Start
Jul 2016
Primary completionActual
Oct 31, 2021
CompletionActual
Mar 31, 2022
Results first posted
May 23, 2025
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02596126
Lead sponsor
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Collaborators
Charite University, Berlin, Germany, Centre Hospitalier Universitaire de Besancon, Wroclaw Medical University, Semmelweis University, General University Hospital, Prague, Servicio Madrileño de Salud, Madrid, Spain, London School of Hygiene and Tropical Medicine, Ferrer Internacional S.A., Istituto Di Ricerche Farmacologiche Mario Negri
Responsible party
Sponsor
First posted
Nov 4, 2015
Start date
Jul 2016
Primary completion
Oct 31, 2021
Completion
Mar 31, 2022
Results posted
May 23, 2025
Last update
May 23, 2025

Study contacts

Valentin Fuster, MD, PhD
principal investigator · Centro Nacional de Investigaciones Cardiovasculares Carlos III
Jose Maria Castellano Vazquez, MD, PhD
study director · Centro Nacional de Investigaciones Cardiovasculares Carlos III

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion